- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sun Pharma to buy 60 percent stake in Vivaldis Health and Foods for Rs 143 crore
![Sun Pharma to buy 60 percent stake in Vivaldis Health and Foods for Rs 143 crore Sun Pharma to buy 60 percent stake in Vivaldis Health and Foods for Rs 143 crore](https://medicaldialogues.in/h-upload/2022/04/08/750x450_173873-acquisition.webp)
Mumbai: Pharma major, Sun Pharmaceutical Industries Limited, has entered into an agreement to acquire 60 percent shareholding in Vivaldis Health And Foods Private Limited from its existing shareholders with the remaining 40 percent shareholding to be acquired in the future as per certain terms and conditions.
"The cost of acquisition is Rs 143.30 crores subject to customary closing adjustments for 60 percent shareholding," the company stated in a recent BSE filing. The company expects to complete the said acquisition by the end of May 2023.
Medical Dialogues team had earlier reported that Sun Pharmaceutical Industries Limited had successfully completed the acquisition of Concert Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company.
Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates.
Read also: Osteoarthritis candidate MM-II shows durable pain relief in global phase 2b study: Sun Pharma
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751